|Day Low/High||1.99 / 2.04|
|52 Wk Low/High||0.94 / 2.90|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATHX, BMY, HDSN, NX, OEC, PMT Downgrades: ALSK, CENX, CLI, EVR, MLP, PII, UFPT Initiations: BPMC, EVA Read on to get TheStreet Quant Ratings' detailed report:
Trade-Ideas LLC identified Athersys (ATHX) as a strong on high relative volume candidate
Management to Host Conference Call at 4:30pm EST Today
About that 17% bump in Athersys' stock price Thursday: Don't be a sucker.
Athersys (ATHX) stock is up after the company announced positive results from the analysis of one year follow-up data from a Phase 2 study of its therapy for ischemic strokes.
Data Presented at 2016 International Stroke Conference Demonstrate Statistically Significant Improvement in Excellent Outcomes When Evaluating All Subjects and Key Subgroups
Multiple Presentations by Leading Stroke Clinical Investigators
Special Event to be Held Thursday, February 4, 2016, at the Harvard Club of New York City
Study Demonstrates Stem Cell Therapy Provides Significant Benefit in Hypoxic-Ischemic Injury Model in Large Animal Model
Athersys (ATHX) stock is surging after the company announced a license agreement with Healios for treatment of strokes.
Alliance to Focus on Development and Commercialization of Regenerative Medicine Products for Stroke and Other Potential Indications Using New Regulatory Framework in Japan
These under-$10 stocks look poised to break out and trade higher from current levels.